AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

Journal of Drugs in Dermatology JDD Article about Exploring the Potential Link Between Minoxidil Use and Rosacea Using A Real-World Data Base

What Every Dermatologist Should Know About Hair

| Featured Articles, Hidradenitis Suppurativa, Latest News | No Comments
Dive into JDD’s hair resources! You told us you wanted more on hair, so JDD listened. Hair disorders—from everyday androgenetic hair loss to the disruptive, emotionally fraught cases of alopecia…

JDD Podcast: Inhaled, Applied, Prescribed: Steroids Through the Allergy Lens

| Featured Articles, Latest News, Podcast Highlights, The JDD Steroid Stewardship Podcast | No Comments
Inhaled, Applied, Prescribed: Steroids Through the Allergy Lens Guest: Dr. Bob Geng We all reach for corticosteroids—whether it's that trusty tube, inhaler, or systemic burst (or maybe all of the…
Journal of Drugs in Dermatology JDD Article about Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel

| Atopic Dermatitis, Featured Articles, Latest News | No Comments
Have you read this JDD consensus on advanced topical nonsteroidal therapies for atopic dermatitis? Dive into this recent article from the March issue! A seven-dermatologist expert panel used a structured…

Leave a Reply